Jeff Poulton
CFO at Alnylam Pharmaceuticals
Now I'd like to turn to our financial guidance for 2025, where we are substantially increasing our net product revenue guidance, driven by the strong early launch performance of VANBUTRA and ATTR cardiomyopathy, with specific details as follows: We are increasing our net product revenue guidance from a range of 2,050,000,000.00 to $2,250,000,000 to a revised range of 2,650,000,000.00 to $2,800,000,000 representing a $575,000,000 or 27% increase from the midpoint of the prior guidance to the midpoint of the updated guidance. The combined full year growth compared to 2024 is a 66% increase at the midpoint of the guidance range. On a franchise level, the guidance is broken down as follows. We are modestly increasing the midpoint of our total rare franchise guidance by raising the bottom end of our prior guidance range by $25,000,000 and leaving the top end of our guidance unchanged, resulting in revised rare product sales guidance of $475,000,000 to $525,000,000 We are materially increasing our total TTR guidance range from 1,600,000,000.0 to $1,725,000,000 to a revised range of 2,175,000,000.000 to $2,275,000,000 representing a 34% increase or more than $550,000,000 at the midpoint. Let me provide some additional context, which highlights the impact of the cardiomyopathy launch on our TTR franchise growth based on our upgraded guidance.
